[
  {
    "ts": null,
    "headline": "Raymond James Upgrade and Organic Growth Story Might Change The Case For Investing In Stryker (SYK)",
    "summary": "Recently, Raymond James upgraded Stryker to “Outperform,” highlighting its track record of 10%-plus organic revenue growth and positioning in medical technology across orthopedics, surgical tools, neurotechnology, and patient care. The upgrade underscores how Stryker’s consistent organic expansion and perceived quality within its sector are influencing how analysts reassess its prospects relative to peers. Next, we’ll examine how this Raymond James upgrade, emphasizing Stryker’s sustained...",
    "url": "https://finnhub.io/api/news?id=f551ee1161da06dd324fa36e7dc361b9cb9b07248e578c63defa220e41d96d36",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767827707,
      "headline": "Raymond James Upgrade and Organic Growth Story Might Change The Case For Investing In Stryker (SYK)",
      "id": 138033406,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "SYK",
      "source": "Yahoo",
      "summary": "Recently, Raymond James upgraded Stryker to “Outperform,” highlighting its track record of 10%-plus organic revenue growth and positioning in medical technology across orthopedics, surgical tools, neurotechnology, and patient care. The upgrade underscores how Stryker’s consistent organic expansion and perceived quality within its sector are influencing how analysts reassess its prospects relative to peers. Next, we’ll examine how this Raymond James upgrade, emphasizing Stryker’s sustained...",
      "url": "https://finnhub.io/api/news?id=f551ee1161da06dd324fa36e7dc361b9cb9b07248e578c63defa220e41d96d36"
    }
  },
  {
    "ts": null,
    "headline": "Smith & Nephew: Improving And Undervalued, But Mind The Knees",
    "summary": "Smith & Nephew (SNN) outlook: sports medicine and wound care strength vs ortho weakness. Read here for an investment analysis of SNN stock.",
    "url": "https://finnhub.io/api/news?id=f336e8c2ffa3486b91c407c6181e8b04c6ff13620e75386f6cc8cbaeb3c92eb8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767826050,
      "headline": "Smith & Nephew: Improving And Undervalued, But Mind The Knees",
      "id": 138031327,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2231363415/image_2231363415.jpg?io=getty-c-w1536",
      "related": "SYK",
      "source": "SeekingAlpha",
      "summary": "Smith & Nephew (SNN) outlook: sports medicine and wound care strength vs ortho weakness. Read here for an investment analysis of SNN stock.",
      "url": "https://finnhub.io/api/news?id=f336e8c2ffa3486b91c407c6181e8b04c6ff13620e75386f6cc8cbaeb3c92eb8"
    }
  },
  {
    "ts": null,
    "headline": "Despite Reassurances On Growth, The Market Hasn't Warmed To Stryker",
    "summary": "Stryker outlook: 9%+ FYâ26 growth, margin leverage, and attractive valuation vs. med-tech peers. See why I rate SYK stock a Buy.",
    "url": "https://finnhub.io/api/news?id=2b11314af3888fd0f7052c07cd034563c77da31fc224ffbc6a51031c9c0862cf",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767775540,
      "headline": "Despite Reassurances On Growth, The Market Hasn't Warmed To Stryker",
      "id": 138026429,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1300437730/image_1300437730.jpg?io=getty-c-w1536",
      "related": "SYK",
      "source": "SeekingAlpha",
      "summary": "Stryker outlook: 9%+ FYâ26 growth, margin leverage, and attractive valuation vs. med-tech peers. See why I rate SYK stock a Buy.",
      "url": "https://finnhub.io/api/news?id=2b11314af3888fd0f7052c07cd034563c77da31fc224ffbc6a51031c9c0862cf"
    }
  },
  {
    "ts": null,
    "headline": "1 Oversold Stock Primed to Rebound and 2 That Underwhelm",
    "summary": "Rock-bottom prices don't always mean rock-bottom businesses. The stocks we're examining today have all touched their 52-week lows, creating a classic investor's dilemma: bargain opportunity or value trap?",
    "url": "https://finnhub.io/api/news?id=45a7078899fc798a8167574aec231282405c52159a60dbc659bb57a217699994",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767760532,
      "headline": "1 Oversold Stock Primed to Rebound and 2 That Underwhelm",
      "id": 138025918,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "SYK",
      "source": "Yahoo",
      "summary": "Rock-bottom prices don't always mean rock-bottom businesses. The stocks we're examining today have all touched their 52-week lows, creating a classic investor's dilemma: bargain opportunity or value trap?",
      "url": "https://finnhub.io/api/news?id=45a7078899fc798a8167574aec231282405c52159a60dbc659bb57a217699994"
    }
  }
]